Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07533032 · ClinicalTrials.gov registry record · NA
Dose-Response Effect of Phosphatidylserine on eSport Performance
A NA study, sponsored by Lindenwood University.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
NCT07533032 is a NA study that has completed, run by Lindenwood University. The registered enrollment target is 80 participants.
The verdict
NCT07533032, a NA study, has completed, sponsored by Lindenwood University.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
Study Summary
This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive placebo, 100 mg phosphatidylserine, or 200 mg phosphatidylserine daily for 6 weeks. Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether daily phosphatidylserine supplementation can improve performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Phosphatidylserine (100 mg)
- DIETARY_SUPPLEMENT Phosphatidylserine (200 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-06-15 |
| Est. Completion | 2025-04-14 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07533032
The ClinicalTrials.gov registry entry for NCT07533032 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindenwood University, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07533032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07533032 about?
NCT07533032 is a clinical study titled "Dose-Response Effect of Phosphatidylserine on eSport Performance". This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-control...
What is the current status of trial NCT07533032?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2021-06-15. Estimated completion is 2025-04-14.
What interventions are being tested in trial NCT07533032?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Phosphatidylserine (100 mg) (DIETARY_SUPPLEMENT), Phosphatidylserine (200 mg) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07533032?
This trial is sponsored by Lindenwood University, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.